Pennsylvania-yakavakirwa JBS Sayenzi yakati nhasi yakagamuchira iyo $ 3 miriyoni Bridge Mubairo weDiki Bhizinesi Innovation Research IIB kubva kuNational Cancer Institute. Iyo kambani yakagadzira yekutanga mvura biopsy chigadzirwa, inova weti DNA yekuongorora yekutanga chiropa cell cancer (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of gomarara rechiropa. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating tumarara DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS yakati yakabatana naJames Hamilton weJohns Hopkins University Medical Center naHie-Won Hann weThomas University Hospital kufambisira mberi kuvandudzwa kwekuongororwa kwegomarara rechiropa.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
